glucagon like peptide 1 glp 1 receptor agonist medications Comparing Ozempic, Wegovy and Other GLP-1 Drugs Discovery of GLP-1–Based Drugs for

"We always focus on what's most important to them and why they are taking this GLP-1

Tirzepatides dual GIP/GLP 1 mechanism appears even more potent

Thus, this modest increase in LDL-C may be misleading regarding ASCVD risk, as patients with obesity may have a higher concentration of atherogenic small, dense LDL particles, and therefore high levels of apoB for a given blood LDL-C [10, 13]

Luthi, H

More recent research continues to suggest that there may be a signal worth paying attention to

Some recent safety reviews have also examined whether Wegovy linked risks may include NAION, a rare optic nerve condition that can cause sudden vision loss